The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Zoledronic acid inhibits adjuvant letrozole-associated bone loss in postmenopausal Japanese women with early breast cancer.
S. Takahashi
No relevant relationships to disclose
T. Iwase
No relevant relationships to disclose
N. Kohno
No relevant relationships to disclose
T. Ishikawa
No relevant relationships to disclose
T. Taguchi
No relevant relationships to disclose
M. Takahashi
No relevant relationships to disclose
J. Horiguchi
No relevant relationships to disclose
S. Nakamura
No relevant relationships to disclose
M. Fukunaga
No relevant relationships to disclose
S. Noguchi
No relevant relationships to disclose